Study of EVO756 in Adults With Migraine
Purpose
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
Condition
- Migraine
Eligibility
- Eligible Ages
- Between 18 Years and 64 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Adults aged 18 to <65 years - Migraine with or without aura, per ICHD-3 criteria - History of failure with prior preventive migraine treatments - Not currently using migraine preventive therapy
Exclusion Criteria
- Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders - Use of certain medications - Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Dose 1 |
Orally administered EVO756, Dose 1 (Daily) |
|
|
Experimental Dose 2 |
Orally administered EVO756, Dose 2 (Daily) |
|
|
Placebo Comparator Placebo |
Placebo control (Daily) |
|
Recruiting Locations
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida 32256
Jacksonville, Florida 32256
Clinical Neuroscience Solutions, Inc.
Orlando, Florida 32819
Orlando, Florida 32819
Eximia Research NC
Raleigh, North Carolina 27607
Raleigh, North Carolina 27607
Clinical Trials of South Carolina
Charleston, South Carolina 29406
Charleston, South Carolina 29406
FutureSearch Trials of Neurology
Austin, Texas 78731
Austin, Texas 78731
FutureSearch Trials of Dallas
Dallas, Texas 75251
Dallas, Texas 75251
More Details
- Status
- Recruiting
- Sponsor
- Evommune, Inc.